SummaryRMgm-5345
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption, Introduction of a transgene |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 37708854 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei ANKA |
Name parent line/clone | P. berghei ANKA 507cl1 (RMgm-7) |
Other information parent line | P.berghei ANKA 507cl1 (RMgm-7) is a reference ANKA mutant line that expresses GFP under control of the constitutive eef1a promoter. This reference line does not contain a drug-selectable marker (PubMed: PMID: 16242190). |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | Ukegbu CV, Vlachou D, Christophides GK |
Name Group/Department | Department of Life Sciences |
Name Institute | Imperial College London |
City | London |
Country | UK |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-5345 |
Principal name | Δsto |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Normal fertilization and ookinete production. However, ookinetes displayed a great defect in midgut invasion and mutant ookinetes exhibit strong motility defects. |
Oocyst | A 99% decrease of mean oocyst numbers |
Sporozoite | Very few to none salivary gland sporozoites |
Liver stage | No infection of mice by mosquito bite |
Additional remarks phenotype | Mutant/mutation Additional information From the paper: We used PlasmoGEM disruption vectors for STONES and CRYSP and conventional disruption vectors for CRONE, ROVER and SPM1 to generate clonal P. berghei mutants in the c507 GFP-expressing wild type (wt) line. The ookinete to oocyst defective phenotypes of the Δsto and Δrov parasites were further investigated in midgut invasion assays using infections of A. coluzzii silenced for CTL4. CTL4 is a key hemolymph regulator of melanization, and its silencing leads to readily melanized P. berghei ookinetes that have succeeded in invading the midgut epithelium and reached the sub-epithelial space. The results showed that both Δsto and Δrov ookinetes displayed a great defect in midgut invasion as the number of melanized ookinetes were significantly reduced compared to wt controls. Defective midgut invasion can be due to the inability of ookinetes to move, and we assessed this by measuring the forward speed of ookinetes on matrigel. The results confirmed that both Δsto and Δrov mutants exhibit strong motility defects which likely cause their decreased ability to traverse the midgut epithelium and form oocysts and sporozoites. To further examine this, Δsto and Δrov ookinetes were injected directly into the hemocoel to assess if the oocyst and sporozoite defective phenotypes could be rescued. Indeed, it has been previously shown that mosquito transmission of P. berghei mutants with ookinete motility defects can be rescued if midgut invasion is bypassed. The result confirmed that this was the case for both Δsto and Δrov, as both the salivary gland sporozoite numbers and the ability of mutants for mouse transmission through bite-back were restored. The endogenous STONES, ROVER, CRYSP and CRONE genes were tagged with C-terminal 3xHA tag via double crossover homologous recombination in the c507 line, and the resulting transgenic lines were designated stones::3xha (RMgm-5350), rover::3xha (RMgm-5351), crysp::3xha (RMgm-5352) and crone::3xha (RMgm-5353), respectively We first analyzed STONES and ROVER, of which the disruption leads to defective ookinete phenotypes. The STONES::3xHA protein could not be detected at the predicted size of ~125 kDa in Triton X-100 soluble extracts of blood stages, gametocytes or mature ookinetes. Instead, a band size of ~16 kDa was detected predominantly in mature ookinetes and less in blood stages and gametocytes. However, in Triton X-100 insoluble extracts, a band of ~80 kDa was specifically detected in mature ookinetes, with traces of it also in gametocytes. As the full length protein was never detected in any of the extracts, these results suggest that STONES undergoes proteolytic processing, and that its C-terminal ~80kDa fragment is embedded within the membrane owing to the multiple transmembrane domains. The ROVER::3xHA protein was detected only in mature ookinetes as 2 bands: the first at the expected size of ~43 kDa, and the second, more predominant band at ~25 kDa. This may indicate proteolytic cleavage of the protein. In immunofluorescence assays, STONES::3xHA was specifically detected at a distinctive membrane region located on the convex side of the mature ookinete, posterior to the apical structure. This region is critical for ookinete motility and has been termed Ookinete Extrados Site (OES). In non- riton X-100 treated mature ookinetes, no signal at the OES could be detected, suggesting that the N-terminal HA-tagged part of STONES is intracellular, which is consistent with its topology predictions. ROVER::3xHA was localized in discrete cytoplasmic spots of mature ookinetes, resembling exocytic vesicles, commonly but not always positioned toward the apical end and in proximity to the cell membrane. Western blot analyses using an anti-HA antibody detected a ~33 kDa CRYSP::3XHA protein in extracts from purified in vitro cultured crysp::3xha ookinetes and, to a much lower levels, from gametocytes, both prior to and after induction of gametogenesis. Similarly, the ~33 kDa CRONE::3xHA protein was detected in ookinete and, less so, gametocyte extracts of the crone::3xha line. We examined the cellular localization of the two proteins in immunofluorescence assays of gametocytes and ookinetes. In both cases, a clear and distinct spot pattern that always colocalized with the hemozoin (visible in bright field) was detected in the ookinete. This pattern is the hallmark of crystalloid localization in P. berghei. Multiple ookinete observations revealed that the number of spots varied from 1 to 3, which were always in association with the hemozoin containing vesicles. The two proteins were henceforth named CRONE for “crystalloid oocyst not evolving” and CRYSP for “crystalloid needed for sporozoites”. In the crone::3xha line, a vesicle-like albeit less prominent staining pattern was also detected in the female gametocytes, consistent with the high CRONE protein abundance in gametocyte extracts. Crystalloids are organelles known to be specific to ookinetes and young oocysts, thought to form soon after fertilization through active assembly of endoplasmic reticulum-derived vesicles. Some of the known crystalloid proteins are also synthesized in the gametocytes. Therefore, one can speculate that the CRONE::3xHA-stained gametocyte vesicles are crystalloid precursor subunits. Whilst this may be true, the expression of CRONE in gametocytes could be due to the CRONE::3xHA expression design that used the P. berghei dihydrofolate reductase (DHFR) 3′ untranslated region (UTR). Cis-acting elements in the 5′ UTR or 3′ UTR of DOZI- regulated genes have been shown to be important for translational repression. Indeed, a previous study that expressed a GFP-tagged version of CRONE using the 3′ UTR of P28 that is also translationally repressed by DOZI found that GFP is restricted to the ookinete crystalloid. To examine this, we raised rabbit polyclonal antibodies against a codon-optimized fragment of CRONE (amino acids 24-235) expressed in Escherichia coli cells. Using these antibodies in immunofluorescence assays, we detected a clear ookinete crystalloid signal, but this signal was absent from gametocytes. This indicated that the gametocyte signal detected in the crone::3xha line is likely due to leaky DOZI post-transcriptional repression Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0413500 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0315700 | ||||||||||||||||||||||||
Gene product | conserved Plasmodium membrane protein, unknown function | ||||||||||||||||||||||||
Gene product: Alternative name | STONES (still ookinetes on the extrados site) | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | (Linear) plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | Yes | ||||||||||||||||||||||||
Name of PlasmoGEM construct/vector | - | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Partial | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | 84% deletion of the coding sequence of STONES | ||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr/yfcu | ||||||||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | For disruption of STONES and CRYSP, we used the PbGEM_230494 and PbGEM_058356 PlasmoGEM vectors, respectively. The targeting cassettes were released by NotI digestion resulting in 84% and 80% deletion of the CDS of STONES and CRYSP at the 5′ end. Partial (66%) knockout of CRONE and full knockout of ROVER and SPM1 was carried out by double-crossover homologous recombination in the c507 line. For this, EcoRI/BamHI 5′ homology arms and Apa/HindIII 5′ homology arms were amplified from genomic DNA using the primer pairs P1/P2 (588 bp), P5/P6 (728 bp) and P9/P10 (620 bp) and P3/P4 (573 bp), P7/P8 (558 bp) and P11/P12 (648 bp), respectively (Table S9). These fragments were cloned into the Pbs-TgDHFR vector with homology arms flanking a modified Toxoplasma gondii dihydrofolate gene (TgDHFR/TS) cassette that confers resistance to pyrimethamine. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |
top of page | |||||||||||||||||||
Type and details of transgene | |||||||||||||||||||
Is the transgene Plasmodium derived | Transgene: not Plasmodium | ||||||||||||||||||
Transgene name | GFP | ||||||||||||||||||
top of page | |||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||
Inducable system used | No | ||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||
Type of plasmid/construct | (Linear) plasmid double cross-over | ||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||
Selectable marker used to select the mutant parasite | gfp (FACS) | ||||||||||||||||||
Promoter of the selectable marker | eef1a | ||||||||||||||||||
Selection (positive) procedure | FACS (flowsorting) | ||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||
Additional remarks genetic modification | The GFP gene (1 copy) has been inserted into the 230p locus (PBANKA_030600) by double cross-over integration. | ||||||||||||||||||
Additional remarks selection procedure | This reporter mutant expressing GFP does not contain a drug-selectable marker. This mutant has been selected by FACS sorting after transfection based on GFP fluorescence. | ||||||||||||||||||
top of page | |||||||||||||||||||
Other details transgene | |||||||||||||||||||
top of page | |||||||||||||||||||
Promoter | |||||||||||||||||||
Gene Model of Parasite | PBANKA_1133300 | ||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1357100 | ||||||||||||||||||
Gene product | elongation factor 1-alpha | ||||||||||||||||||
Gene product: Alternative name | eef1a | ||||||||||||||||||
| |||||||||||||||||||
top of page | |||||||||||||||||||
3'-UTR | |||||||||||||||||||
Gene Model of Parasite | PBANKA_0719300 | ||||||||||||||||||
Gene product | bifunctional dihydrofolate reductase-thymidylate synthase, putative | ||||||||||||||||||
Gene product: Alternative name | dhfr/ts | ||||||||||||||||||
| |||||||||||||||||||
Insertion/Replacement locus | |||||||||||||||||||
Replacement / Insertion | Replacement locus | ||||||||||||||||||
Gene Model of Parasite | PBANKA_0306000 | ||||||||||||||||||
Gene product | 6-cysteine protein | ||||||||||||||||||
Gene product: Alternative name | 230p | ||||||||||||||||||
| |||||||||||||||||||
top of page |